Literature DB >> 29916386

Type 1 diabetes.

Linda A DiMeglio1, Carmella Evans-Molina2, Richard A Oram3.   

Abstract

Type 1 diabetes is a chronic autoimmune disease characterised by insulin deficiency and resultant hyperglycaemia. Knowledge of type 1 diabetes has rapidly increased over the past 25 years, resulting in a broad understanding about many aspects of the disease, including its genetics, epidemiology, immune and β-cell phenotypes, and disease burden. Interventions to preserve β cells have been tested, and several methods to improve clinical disease management have been assessed. However, wide gaps still exist in our understanding of type 1 diabetes and our ability to standardise clinical care and decrease disease-associated complications and burden. This Seminar gives an overview of the current understanding of the disease and potential future directions for research and care.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29916386      PMCID: PMC6661119          DOI: 10.1016/S0140-6736(18)31320-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  234 in total

1.  The role of proteomics in assessing beta-cell dysfunction and death in type 1 diabetes.

Authors:  Ernesto S Nakayasu; Wei-Jun Qian; Carmella Evans-Molina; Raghavendra G Mirmira; Decio L Eizirik; Thomas O Metz
Journal:  Expert Rev Proteomics       Date:  2019-06-24       Impact factor: 3.940

2.  Comprehensive Proteomics Analysis of Stressed Human Islets Identifies GDF15 as a Target for Type 1 Diabetes Intervention.

Authors:  Ernesto S Nakayasu; Farooq Syed; Sarah A Tersey; Marina A Gritsenko; Hugh D Mitchell; Chi Yuet Chan; Ercument Dirice; Jean-Valery Turatsinze; Yi Cui; Rohit N Kulkarni; Decio L Eizirik; Wei-Jun Qian; Bobbie-Jo M Webb-Robertson; Carmella Evans-Molina; Raghavendra G Mirmira; Thomas O Metz
Journal:  Cell Metab       Date:  2020-01-09       Impact factor: 27.287

Review 3.  Nanotechnology in cell replacement therapies for type 1 diabetes.

Authors:  Alexander U Ernst; Daniel T Bowers; Long-Hai Wang; Kaavian Shariati; Mitchell D Plesser; Natalie K Brown; Tigran Mehrabyan; Minglin Ma
Journal:  Adv Drug Deliv Rev       Date:  2019-02-02       Impact factor: 15.470

4.  Abnormalities in proinsulin processing in islets from individuals with longstanding T1D.

Authors:  Emily K Sims; Farooq Syed; Julius Nyalwidhe; Henry T Bahnson; Leena Haataja; Cate Speake; Margaret A Morris; Appakalai N Balamurugan; Raghavendra G Mirmira; Jerry Nadler; Teresa L Mastracci; Peter Arvan; Carla J Greenbaum; Carmella Evans-Molina
Journal:  Transl Res       Date:  2019-08-09       Impact factor: 7.012

5.  A study of 51 subtypes of peripheral blood immune cells in newly diagnosed young type 1 diabetes patients.

Authors:  A Oras; A Peet; T Giese; V Tillmann; R Uibo
Journal:  Clin Exp Immunol       Date:  2019-06-21       Impact factor: 4.330

Review 6.  New Evidence of Exocrine Pancreatopathy in Pre-symptomatic and Symptomatic Type 1 Diabetes.

Authors:  Federica Vecchio; Gloria Messina; Anna Giovenzana; Alessandra Petrelli
Journal:  Curr Diab Rep       Date:  2019-08-31       Impact factor: 4.810

7.  Longitudinal proteomics analysis in the immediate microenvironment of islet allografts during progression of rejection.

Authors:  Oscar Alcazar; Luis F Hernandez; Ernesto S Nakayasu; Paul D Piehowski; Charles Ansong; Midhat H Abdulreda; Peter Buchwald
Journal:  J Proteomics       Date:  2020-05-20       Impact factor: 4.044

8.  Lentiviral gene therapy vectors encoding VIP suppressed diabetes-related inflammation and augmented pancreatic beta-cell proliferation.

Authors:  Fulya Erendor; Elif Ozgecan Sahin; Ahter D Sanlioglu; Mustafa Kemal Balci; Thomas S Griffith; Salih Sanlioglu
Journal:  Gene Ther       Date:  2020-07-30       Impact factor: 5.250

9.  Next-Generation HLA Sequence Analysis Uncovers Seven HLA-DQ Amino Acid Residues and Six Motifs Resistant to Childhood Type 1 Diabetes.

Authors:  Lue Ping Zhao; George K Papadopoulos; William W Kwok; Antonis K Moustakas; George P Bondinas; Annelie Carlsson; Helena Elding Larsson; Johnny Ludvigsson; Claude Marcus; Ulf Samuelsson; Ruihan Wang; Chul-Woo Pyo; Wyatt C Nelson; Daniel E Geraghty; Åke Lernmark
Journal:  Diabetes       Date:  2020-08-31       Impact factor: 9.461

10.  MiniMed 670G hybrid closed loop artificial pancreas system for the treatment of type 1 diabetes mellitus: overview of its safety and efficacy.

Authors:  Aria Saunders; Laurel H Messer; Gregory P Forlenza
Journal:  Expert Rev Med Devices       Date:  2019-09-30       Impact factor: 3.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.